Corresponding Author: Manish M. Patel, MD, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS H24-7, Atlanta, GA 30329 (firstname.lastname@example.org).
Accepted for Publication: September 4, 2020.
Published Online: September 17, 2020. doi:10.1001/jama.2020.18796
Author Contributions: Drs Patel and Self had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Patel, Thornburg, Stubblefield, Talbot, Feldstein, Self.
Acquisition, analysis, or interpretation of data: Patel, Thornburg, Stubblefield, Talbot, Coughlin, Self.
Drafting of the manuscript: Patel, Self.
Critical revision of the manuscript for important intellectual content: Thornburg, Stubblefield, Talbot, Coughlin, Feldstein, Self.
Statistical analysis: Patel, Coughlin.
Obtained funding: Patel, Self.
Administrative, technical, or material support: Stubblefield, Talbot, Coughlin, Feldstein, Self.
Supervision: Patel, Thornburg, Self.
Conflict of Interest Disclosures: Dr Coughlin reported US Patent 7,728,110B2, an isolated human monoclonal antibody that specifically binds to SARS-CoV S protein. No other disclosures were reported.
Funding/Support: This work was funded by Centers for Disease Control and Prevention contract 75D30120C07637 (Dr Self).
Role of the Funder/Sponsor: The Centers for Disease Control and Prevention was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The findings and conclusions of this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention.
FJ , Fulcher
JA , Goodman-Meza
et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med
. Published online July 21, 2020. doi:10.1056/NEJMc2025179PubMedGoogle Scholar
WB , Talbot
HK , Feldstein
et al; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients—Nashville, Tennessee. Clin Infect Dis
. 2020;ciaa936. doi:10.1093/cid/ciaa936PubMedGoogle Scholar
L , Segovia-Chumbez
B , Jadi
et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol
. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413PubMedGoogle Scholar